Skip to main content
Top
Published in: BMC Public Health 1/2005

Open Access 01-12-2005 | Research article

Treatment outcome of new culture positive pulmonary tuberculosis in Norway

Authors: Mohamed Guled Farah, Aage Tverdal, Tore W Steen, Einar Heldal, Arne B Brantsaeter, Gunnar Bjune

Published in: BMC Public Health | Issue 1/2005

Login to get access

Abstract

Background

The key elements in tuberculosis (TB) control are to cure the individual patient, interrupt transmission of TB to others and prevent the tubercle bacilli from becoming drug resistant. Incomplete treatment may result in excretion of bacteria that may also acquire drug resistance and cause increased morbidity and mortality. Treatment outcome results serves as a tool to control the quality of TB treatment provided by the health care system. The aims of this study were to evaluate the treatment outcome for new cases of culture positive pulmonary TB registered in Norway during the period 1996–2002 and to identify factors associated with non-successful treatment.

Methods

This was a register-based cohort study. Treatment outcome was assessed according to sex, birthplace, age group, isoniazid (INH) susceptibility, mode of detection and treatment periods (1996–1997, 1998–1999 and 2000–2002). Logistic regression was also used to estimate the odds ratio for treatment success vs. non-success with 95% confidence interval (CI), taking the above variables into account.

Results

Among the 655 patients included, the total treatment success rate was 83% (95% CI 80%–86%). The success rates for those born in Norway and abroad were 79% (95% CI 74%–84%) and 86% (95% CI 83%–89%) respectively. There was no difference in success rates by sex and treatment periods. Twenty-two patients (3%) defaulted treatment, 58 (9%) died and 26 (4%) transferred out. The default rate was higher among foreign-born and male patients, whereas almost all who died were born in Norway. The majority of the transferred out group left the country, but seven were expelled from the country. In the multivariate analysis, only high age and initial INH resistance remained as significant risk factors for non-successful treatment.

Conclusion

Although the TB treatment success rate in Norway has increased compared to previous studies and although it has reached a reasonable target for treatment outcome in low-incidence countries, the total success rate for 1996–2002 was still slightly below the WHO target of success rate of 85%. Early diagnosis of TB in elderly patients to reduce the death rate, abstaining from expulsion of patients on treatment and further measures to prevent default could improve the success rate further.
Appendix
Available only for authorised users
Literature
1.
go back to reference World Health Organization: WHO Tuberculosis Programme: Framework for Effective Tuberculosis Control. Geneva, Switzerland: WHO/ TB/ 94. 179. World Health Organization: WHO Tuberculosis Programme: Framework for Effective Tuberculosis Control. Geneva, Switzerland: WHO/ TB/ 94. 179.
2.
go back to reference Zellweger JP, Coulon P: Outcome of patients treated for tuberculosis in Vaud County, Switzerland. Int J Tuberc Lung Dis. 1998, 2: 372-377.PubMed Zellweger JP, Coulon P: Outcome of patients treated for tuberculosis in Vaud County, Switzerland. Int J Tuberc Lung Dis. 1998, 2: 372-377.PubMed
3.
go back to reference Romanus V, Julander I, Blom-Bulow B, Larsson LO, Normann B, Boman G: Shortages in Swedish tuberculosis care. Good results only in 71 percent of cases after 12-month treatment as shown in a current study [in Swedish]. Läkartidningen. 2000, 97: 5613-5616.PubMed Romanus V, Julander I, Blom-Bulow B, Larsson LO, Normann B, Boman G: Shortages in Swedish tuberculosis care. Good results only in 71 percent of cases after 12-month treatment as shown in a current study [in Swedish]. Läkartidningen. 2000, 97: 5613-5616.PubMed
4.
go back to reference Grzybowski S, Enarson DA: The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc. 1978, 53: 70-75.PubMed Grzybowski S, Enarson DA: The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc. 1978, 53: 70-75.PubMed
5.
go back to reference Winje BA, Heldal E: Tuberculosis Disease in Norway 2002 [in Norwegian]. MSIS-rapport No. 23. 2003, Oslo: Norwegian Institute of Public Health Winje BA, Heldal E: Tuberculosis Disease in Norway 2002 [in Norwegian]. MSIS-rapport No. 23. 2003, Oslo: Norwegian Institute of Public Health
6.
go back to reference Heldal E: Results of tuberculosis treatment in Norway 1995 [in Norwegian]. Nor J Epidemiol. 1997, 7: 231-233. Heldal E: Results of tuberculosis treatment in Norway 1995 [in Norwegian]. Nor J Epidemiol. 1997, 7: 231-233.
7.
go back to reference Broekman JF, Migliori GB, Rieder HL, Lees J, Rutuu P, Loddenkemper R, Raviglione MC: European framework for tuberculosis control and elimination in countries with a low incidence. Eur Respir J. 2002, 19: 765-775. 10.1183/09031936.02.00261402.CrossRef Broekman JF, Migliori GB, Rieder HL, Lees J, Rutuu P, Loddenkemper R, Raviglione MC: European framework for tuberculosis control and elimination in countries with a low incidence. Eur Respir J. 2002, 19: 765-775. 10.1183/09031936.02.00261402.CrossRef
8.
go back to reference Heldal E: Notification of tuberculosis in Norway [in Norwegian]. Nor J Epidemiol. 1995, 5: 15-17. Heldal E: Notification of tuberculosis in Norway [in Norwegian]. Nor J Epidemiol. 1995, 5: 15-17.
9.
go back to reference Bjartveit K: The control of tuberculosis. A handbook for community health service [in Norwegian]. 1996, Oslo: National Health Screening Service and Norwegian Board of Health Bjartveit K: The control of tuberculosis. A handbook for community health service [in Norwegian]. 1996, Oslo: National Health Screening Service and Norwegian Board of Health
10.
go back to reference World Health Organization: Global Tuberculosis Control. WHO Report 1999. Geneva, Switzerland, WHO/CDS/CPC/TB/99.259. World Health Organization: Global Tuberculosis Control. WHO Report 1999. Geneva, Switzerland, WHO/CDS/CPC/TB/99.259.
11.
go back to reference The Norwegian Institute of Public Health: Manual of tuberculosis control and prevention in Norway [in Norwegian]. 2002, Oslo: The Institute The Norwegian Institute of Public Health: Manual of tuberculosis control and prevention in Norway [in Norwegian]. 2002, Oslo: The Institute
12.
go back to reference Diel R, Nieman S: Outcome of tuberculosis treatment in Hamburg: a survey, 1997–2001. Int J Tuberc Lung Dis. 2003, 7: 124-131.PubMed Diel R, Nieman S: Outcome of tuberculosis treatment in Hamburg: a survey, 1997–2001. Int J Tuberc Lung Dis. 2003, 7: 124-131.PubMed
13.
go back to reference Dahle UR, Sandven P, Heldal E, Caugant DA: Molecular epidemiology of Mycobacterium tuberculosis in Norway. J Clin Microbiol. 2001, 39: 1802-1807. 10.1128/JCM.39.5.1802-1807.2001.CrossRefPubMedPubMedCentral Dahle UR, Sandven P, Heldal E, Caugant DA: Molecular epidemiology of Mycobacterium tuberculosis in Norway. J Clin Microbiol. 2001, 39: 1802-1807. 10.1128/JCM.39.5.1802-1807.2001.CrossRefPubMedPubMedCentral
14.
go back to reference The Royal Ministry of Health: The Control of tuberculosis [in Norwegian]. 2002, Oslo:The Ministry The Royal Ministry of Health: The Control of tuberculosis [in Norwegian]. 2002, Oslo:The Ministry
15.
go back to reference Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR: A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: Implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002, 6: 1114-1117.PubMed Fielder JF, Chaulk CP, Dalvi M, Gachuhi R, Comstock GW, Sterling TR: A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: Implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002, 6: 1114-1117.PubMed
16.
go back to reference Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R: Standardized tuberculosis treatment outcome monitoring in Europe. Eur Respir J. 1998, 12: 505-510. 10.1183/09031936.98.12020505.CrossRefPubMed Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R: Standardized tuberculosis treatment outcome monitoring in Europe. Eur Respir J. 1998, 12: 505-510. 10.1183/09031936.98.12020505.CrossRefPubMed
17.
go back to reference American Thoracic Society and Center for Disease Control and Prevention: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000, 161: 221-247.CrossRef American Thoracic Society and Center for Disease Control and Prevention: Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000, 161: 221-247.CrossRef
18.
go back to reference Naalsund A, Heldal E, Johansen B, Kongerud J, Boe J: Deaths from pulmonary tuberculosis in low-incidence country. Journal of Internal Medicine. 1994, 236: 137-142.CrossRefPubMed Naalsund A, Heldal E, Johansen B, Kongerud J, Boe J: Deaths from pulmonary tuberculosis in low-incidence country. Journal of Internal Medicine. 1994, 236: 137-142.CrossRefPubMed
19.
go back to reference Rieder LH, Bloch AB, Snider DE: Tuberculosis diagnosed at death in the United States. Chest. 1991, 100: 678-681.CrossRefPubMed Rieder LH, Bloch AB, Snider DE: Tuberculosis diagnosed at death in the United States. Chest. 1991, 100: 678-681.CrossRefPubMed
20.
go back to reference Xie HJ, Enarson DA, Chao CW, Allen EA, Grzybowski S: Deaths in tuberculosis patients in British Columbia, 1980–1984. Tuber Lung Dis. 1992, 73: 77-82. 10.1016/0962-8479(92)90059-S.CrossRefPubMed Xie HJ, Enarson DA, Chao CW, Allen EA, Grzybowski S: Deaths in tuberculosis patients in British Columbia, 1980–1984. Tuber Lung Dis. 1992, 73: 77-82. 10.1016/0962-8479(92)90059-S.CrossRefPubMed
21.
go back to reference Zafran N, Heldal E, Pavlovic S, Vukovic D, Boe J: Why do our patients die of active tuberculosis in the era of effective therapy?. Tuberc Lung Dis. 1994, 75: 329-333. 10.1016/0962-8479(94)90077-9.CrossRef Zafran N, Heldal E, Pavlovic S, Vukovic D, Boe J: Why do our patients die of active tuberculosis in the era of effective therapy?. Tuberc Lung Dis. 1994, 75: 329-333. 10.1016/0962-8479(94)90077-9.CrossRef
22.
go back to reference Heldal E, Dahle UR, Sandven P, Caugant DA, Brattaas N, Waaler HT, Enarson DA, Tverdal A, Kongerud J: Risk factors for recent transmission of Mycobacterium tuberculosis. Eur Respir J. 2003, 22: 637-642.CrossRefPubMed Heldal E, Dahle UR, Sandven P, Caugant DA, Brattaas N, Waaler HT, Enarson DA, Tverdal A, Kongerud J: Risk factors for recent transmission of Mycobacterium tuberculosis. Eur Respir J. 2003, 22: 637-642.CrossRefPubMed
23.
go back to reference Nolan CM, Goldberg SV: Treatment of Isoniazid-resistant tuberculosis with isoniazid, rifampicin, ethambutol and pyrazinamide for 6 months. Int J Tuberc Lung Dis. 2002, 6: 952-958.PubMed Nolan CM, Goldberg SV: Treatment of Isoniazid-resistant tuberculosis with isoniazid, rifampicin, ethambutol and pyrazinamide for 6 months. Int J Tuberc Lung Dis. 2002, 6: 952-958.PubMed
Metadata
Title
Treatment outcome of new culture positive pulmonary tuberculosis in Norway
Authors
Mohamed Guled Farah
Aage Tverdal
Tore W Steen
Einar Heldal
Arne B Brantsaeter
Gunnar Bjune
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2005
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-5-14

Other articles of this Issue 1/2005

BMC Public Health 1/2005 Go to the issue